Novartis acquires pain company Spinifex for $200mm up front
Executive Summary
Novartis AG acquired private Australian biotech Spinifex Pharmaceuticals Pty. Ltd. (neurology) for $200mm up front, approximately a 3x step-up to its investors, which have put $69mm into the company.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice